Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pfizer Acquires Biohaven for $11.6B
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 18, 2022 3:11pm
142 Views
Post# 34693274

RE:Pfizer Acquires Biohaven for $11.6B

RE:Pfizer Acquires Biohaven for $11.6B
Forestview wrote: Could pharmaceutical acquisitions be starting up again...this is Pfizer's first acquisition since 2017.

https://www.siliconrepublic.com/business/pfizer-biohaven-acquisition-migraine-nurtec-odt-medication#:~:text=Acquiring%20Biohaven%20will%20allow%20Pfizer,that%20treat%20and%20prevent%20migraines


There are many reasons why Big Pharma needs to really work on their future drug portfolios - from governments looking to get pricing down - to some Big Pharmas who made bad calls on acquisitions (Bayer and Round-up) - to CEOs getting ousted (Biogen - AD) - to big drugs coming off patent by 2026-2030.  There are many reasons why Big Pharma needs to make wise decisions.

We're just not in the running in 2022 (IMO) - but that's OK ... stars are aligning ... especially when you look at the cost of opioids going up (disposal education/stamped envelopes for disposal), Doctors not wanting to deal with opioids and better education out there about the damage from NSAIDs (specifically Aspirin right now).  

It's going to get really interesting - I think.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities